ADAPY

Insider Trades

Name	Value	Action	Price	Last Price
Wood GavinChief Financial Officer $95096k shares SellSep 2, 2025 $0.0099 $0.0087
Bertrand William C JRChief Operating Officer $2.1k207k shares SellAug 28, 2025 $0.0101 $0.0087
Behbahani AliDirector $176k14.7M shares SellAug 18, 2025 $0.012 $0.0087
Behbahani AliDirector $53k4.8M shares SellAug 15, 2025 $0.011 $0.0087
EcoR1 Capital, LLC10 Percent Owner $2.8M27.4M shares SellJul 30, 2025 $0.1021 $0.0087
EcoR1 Capital, LLC10 Percent Owner $272k2.7M shares SellJul 29, 2025 $0.1012 $0.0087

Trade ADAPY

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.

CEO: Christopher James Hill
IPO Date: May 6, 2015

Market Data

Open: $0.04
High: $0.04
Low: $0.031
Volume: 518.4K
Avg Volume: 440K
52W High: $0.358
52W Low: $0.001

Valuation

Market Cap: $11M
Enterprise Value: $33M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-76M
Revenue: $178M
Net Income: $-71M
Cash: $91M
Debt: $74M

Events

EarningsAug 12

EPS est. -0.02